To Be Discontinued Injection Oncology
Gemcitabine Hydrochloride In · 365 days since initial FDA posting
Brand: GEMCITABINE
FDA lists Gemcitabine Hydrochloride In as To Be Discontinued (Hospira, Inc., a Pfizer Company).
No availability text on this FDA row.
Gemcitabine Hydrochloride Injection: To Be Discontinued
FDA availability text is not recorded on this row. Contact your pharmacist if you are affected.
Shortage Details
- Generic Name
- Gemcitabine Hydrochloride Injection
- Manufacturer
- Hospira, Inc., a Pfizer Company
- Dosage Form
- Injection
- Presentation
- Gemcitabine Hydrochloride, Injection, 200 mg/5.26 mL (38 mg/mL), sterile solution in a single-dose glass vial NovaPlus (NDC 0409-0183-25)
- Package NDC
- 0409-0183-25
Status & Timeline
- Status
- To Be Discontinued
- First Reported
- Sep 11, 2025
- Last Updated
- Sep 11, 2025
- Therapeutic Category
- Oncology
Row fields from the FDA Drug Shortages database via openFDA.
Shortage Reason
Discontinuation of the manufacture of the drug
Nearby, Other Gemcitabine Shortage Records
FDA reason on file: Discontinuation of the manufacture of the drug. General shortage guidance lives on the tracker hub.